Conduit Secures Patent in Japan for Lead Autoimmune Therapy, AZD1656 Glucokinase Activator

Conduit Pharmaceuticals Inc. announced that the Japan Patent Office (JPO) has approved a composition of matter patent for its leading candidate, AZD1656. This Glucokinase Activator is being developed to address a variety of autoimmune disorders. This approval was announced in Japanese, following a previous grant in Australia. This marks significant progress in Conduit's strategy to enhance its intellectual property (IP) portfolio and prepare AZD1656 for future out-licensing opportunities.

Dr. David Tapolczay, Chief Executive Officer of Conduit Pharmaceuticals, said in a statement, "This approval represents another significant milestone in our efforts to maximise the value of our intellectual property portfolio. The granting of this patent in Japan, one of the world's largest pharmaceutical markets, underscores the strength of our scientific and intellectual property strategy. We look forward to securing additional approvals in other major markets, further enhancing our global patent coverage and bolstering our out-licensing opportunities."